Updates on Transcranial Magnetic Stimulation Therapy for Major Depressive Disorder - 10/08/18

Doi : 10.1016/j.psc.2018.04.006

Sarah L. Garnaat, PhD ^a,^b, Shiwen Yuan, MD ^a, Haizhi Wang, MD, PhD ^a, Noah S. Philip, MD ^a,^b,^c, Linda L. Carpenter, MD ^a,^b,^⁎
^a Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Box G-BH, Providence, RI 02912, USA
^b Butler Hospital, 345 Blackstone Boulevard, Providence, RI 02906, USA
^c Center for Neurorestoration and Neurotechnology, Providence VA Medical Center, 830 Chalkstone Avenue, Providence, RI 02908, USA

^âˆ—Corresponding author.

Résumé

Transcranial magnetic stimulation has emerged as a treatment option for treatment-resistant depression. While existing data largely support efficacy of transcranial magnetic stimulation for major depressive disorder, ongoing research aims to optimize treatment parameters and identify biomarkers of treatment response. In this article, the authors describe data from controlled trials and ongoing efforts to enhance transcranial magnetic stimulation outcomes for major depressive disorder. Findings from preliminary research aimed at identifying neuroimaging and neurophysiological biomarkers of transcranial magnetic stimulation effects are discussed.

Le texte complet de cet article est disponible en PDF.

Keywords : Noninvasive neuromodulation, Depression, Treatment-resistant depression, Transcranial magnetic stimulation

Plan

Key points

Introduction

Evidence for the efficacy of transcranial magnetic stimulation for depression

Metaanalytic Findings

Findings from Large Multisite, Sham-Controlled, Randomized, Controlled Trials

Naturalistic Findings

Optimizing transcranial magnetic stimulation therapy for major depressive disorder

Imaging biomarkers

Resting state single photon emission computed tomography/PET (metabolic imaging)

Resting state functional connectivity and neural networks

Transcranial Magnetic Stimulation to the Dorsolateral Prefrontal Cortex

Transcranial Magnetic Stimulation to the Dorsomedial Prefrontal Cortex

Summary

	Disclosure Statement: Dr L.L. Carpenter has received consulting income from Magstim, LTD, and Drs N.S. Philip and L.L. Carpenter have received clinical trials/research support from Neuronetics, Neosync, and Janssen. Dr N.S. Philip has been an unpaid scientific advisory board member for Neuronetics. None of the other authors has any relevant commercial or financial disclosures to report.
	This work was supported in part by grants from the National Institute of Mental Health (NIMH) (R25MH101076; S. Yuan & H. Wang) and the US Department of Veterans Affairs (IK2CX000724 and I01RX002450; N.S. Philip). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of NIMH or Department of Veterans Affairs.

Export

Vol 41 - N° 3

P. 419-431 - septembre 2018 Retour au numéro

Article précédent

Vagus Nerve Stimulation : Changing the Paradigm for Chronic Severe Depression?
Scott T. Aaronson, Charles R. Conway

| Article suivant

Clinical Repetitive Transcranial Magnetic Stimulation for Posttraumatic Stress Disorder, Generalized Anxiety Disorder, and Bipolar Disorder
F. Andrew Kozel

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Updates on Transcranial Magnetic Stimulation Therapy for Major Depressive Disorder - 10/08/18

Résumé

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL